Aagami has been appointed as Advisory, Marketing and Sales Consultant to Trustee of IP Portfolio of First-in-Class Non-Opioid Analgesic in c...
Published : 23 Dec 2024
Read MoreAagami Updates of 2024Brought successes for clients 2 investments including from Corporate Venture of a global pharma, for US clients Novel and P...
Published : 19 Dec 2024
Read MoreAagami, Inc. are pleased to announce that our US client has awarded a contract expansion extension to support them in JV/Acquisition/Investment initia...
Published : 14 Nov 2024
Read MoreAs we all know, JP Morgan Healthcare (JPM) week is an annual pilgrimage. Aagami team is already geared up for participation including Biotech Showcase...
Published : 01 Nov 2024
Read MoreAagami has received another contract extension from Japanese client specialising in Nose to Brain delivery.. The client has unlocked efficient de...
Published : 15 Oct 2024
Read MoreWe are very pleased to announce that we had added another Japanese client to Aagami family. Client is a Japan based company specializing in Contr...
Published : 01 Oct 2024
Read MoreAagami is pleased to announce that during the period of July to September, multiple clients have awarded contract extensions to Aagami.US based Geneti...
Published : 16 Sep 2024
Read MoreAagami CEO Dinesh Jain is visiting Japan and Korea and will be meeting 30+ decision makers (mostly in Japanese and Korean companies). This includ...
Published : 04 Sep 2024
Read MoreWe are thrilled to share that Venture Capital Arm of a large global pharma group has invested in two Aagami Client opportunities. Both clients ar...
Published : 06 Aug 2024
Read MoreWe are excited to announce that Aagami is attending the International Life Sciences Partnering Conference – BIO-Europe® 2024 ( Novem...
Published : 12 Jul 2024
Read More